Jin Medical International (Jin Medical International) Operating Income : $2.87 Mil (TTM As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Jin Medical International Operating Income?

Jin Medical International's Operating Income for the six months ended in Sep. 2023 was $1.10 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $2.87 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Jin Medical International's Operating Income for the six months ended in Sep. 2023 was $1.10 Mil. Jin Medical International's Revenue for the six months ended in Sep. 2023 was $9.57 Mil. Therefore, Jin Medical International's Operating Margin % for the quarter that ended in Sep. 2023 was 11.45%.

Jin Medical International's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Jin Medical International's annualized ROC % for the quarter that ended in Sep. 2023 was 15.87%. Jin Medical International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 33.36%.

Jin Medical International Operating Income Historical Data

The historical data trend for Jin Medical International's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jin Medical International Operating Income Chart

Jin Medical International Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Operating Income

2.36

2.63

2.13

2.87

Jin Medical International Semi-Annual Data
	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Operating Income	Get a 7-Day Free Trial			0.79	1.02	1.11	1.77	1.10

Jin Medical International Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.87 Mil.

Jin Medical International (NAS:ZJYL) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Jin Medical International's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	2.192 * ( 1 - 11.18% )	/	( (12.307	+	12.223)	/ 2 )
=	1.9469344	/	12.265
=	15.87 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	31.022	-	5.334	-	( 13.381	-	max(0, 7.476	-	29.089	+	13.381	))
=	12.307

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	32.903	-	3.982	-	( 16.698	-	max(0, 8.924	-	31.116	+	16.698	))
=	12.223

Note: The Operating Income data used here is two times the semi-annual (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Jin Medical International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	2.192	/	( ( (1.583 + max(4.739, 0))	+	(1.481 + max(5.337, 0)) )	/	2 )
=	2.192	/	( ( 6.322	+	6.818 )	/	2 )
=	2.192	/	6.57
=	33.36 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.161	+	6.509	+	0.088999999999999)	-	(5.334	+	0.686	+	8.8817841970013E-16)
=	4.739

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.231	+	5.053	+	0.864)	-	(3.982	+	0.829	+	-1.7763568394003E-15)
=	5.337

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Jin Medical International's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	1.096	/	9.568
	=	11.45 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Jin Medical International Operating Income Related Terms

Thank you for viewing the detailed overview of Jin Medical International's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Jin Medical International (Jin Medical International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jin Medical International Ltd (NAS:ZJYL) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 33 Lingxiang Road,, Wujin District, Jiangsu Province, Changzhou City, CHN, KY1-1205

Website

Jin Medical International Ltd offers rehabilitation equipment. It is primarily engaged in the design, development, manufacturing, and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's products are sold to distributors in both China and in overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, nursing products, and conlo products.